

Charles Y Lin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6776465/publications.pdf>

Version: 2024-02-01

61
papers

14,268
citations

87888

38
h-index

149698

56
g-index

68
all docs

68
docs citations

68
times ranked

22049
citing authors

#	ARTICLE	IF	CITATIONS
1	Master Transcription Factors and Mediator Establish Super-Enhancers at Key Cell Identity Genes. <i>Cell</i> , 2013, 153, 307-319.	28.9	3,202
2	Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers. <i>Cell</i> , 2013, 153, 320-334.	28.9	2,366
3	Transcriptional Amplification in Tumor Cells with Elevated c-Myc. <i>Cell</i> , 2012, 151, 56-67.	28.9	1,262
4	c-Myc Regulates Transcriptional Pause Release. <i>Cell</i> , 2010, 141, 432-445.	28.9	1,104
5	Discovery and Characterization of Super-Enhancer-Associated Dependencies in Diffuse Large B Cell Lymphoma. <i>Cancer Cell</i> , 2013, 24, 777-790.	16.8	635
6	Revisiting Global Gene Expression Analysis. <i>Cell</i> , 2012, 151, 476-482.	28.9	526
7	NF- κ B Directs Dynamic Super Enhancer Formation in Inflammation and Atherogenesis. <i>Molecular Cell</i> , 2014, 56, 219-231.	9.7	507
8	Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer. <i>Nature</i> , 2016, 529, 413-417.	27.8	490
9	Convergence of Developmental and Oncogenic Signaling Pathways at Transcriptional Super-Enhancers. <i>Molecular Cell</i> , 2015, 58, 362-370.	9.7	382
10	BET Bromodomain Proteins Function as Master Transcription Elongation Factors Independent of CDK9 Recruitment. <i>Molecular Cell</i> , 2017, 67, 5-18.e19.	9.7	347
11	Active medulloblastoma enhancers reveal subgroup-specific cellular origins. <i>Nature</i> , 2016, 530, 57-62.	27.8	318
12	In vivo base editing rescues Hutchinson- κ Gilford progeria syndrome in mice. <i>Nature</i> , 2021, 589, 608-614.	27.8	275
13	Models of human core transcriptional regulatory circuitries. <i>Genome Research</i> , 2016, 26, 385-396.	5.5	223
14	Mutant NPM1 Maintains the Leukemic State through HOX Expression. <i>Cancer Cell</i> , 2018, 34, 499-512.e9.	16.8	209
15	Enhancer invasion shapes MYCN-dependent transcriptional amplification in neuroblastoma. <i>Nature Genetics</i> , 2018, 50, 515-523.	21.4	163
16	Small-molecule targeting of brachyury transcription factor addiction in chordoma. <i>Nature Medicine</i> , 2019, 25, 292-300.	30.7	120
17	Taming of the beast: shaping Myc-dependent amplification. <i>Trends in Cell Biology</i> , 2015, 25, 241-248.	7.9	119
18	Triplication of a 21q22 region contributes to B cell transformation through HMG1 overexpression and loss of histone H3 Lys27 trimethylation. <i>Nature Genetics</i> , 2014, 46, 618-623.	21.4	117

#	ARTICLE	IF	CITATIONS
19	Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and CDK12/13. <i>ELife</i> , 2018, 7, .	6.0	109
20	High-fat diet fuels prostate cancer progression by rewiring the metabolome and amplifying the MYC program. <i>Nature Communications</i> , 2019, 10, 4358.	12.8	109
21	Oncogenic Deregulation of EZH2 as an Opportunity for Targeted Therapy in Lung Cancer. <i>Cancer Discovery</i> , 2016, 6, 1006-1021.	9.4	108
22	Dynamic Chromatin Targeting of BRD4 Stimulates Cardiac Fibroblast Activation. <i>Circulation Research</i> , 2019, 125, 662-677.	4.5	105
23	Development of a Selective CDK7 Covalent Inhibitor Reveals Predominant Cell-Cycle Phenotype. <i>Cell Chemical Biology</i> , 2019, 26, 792-803.e10.	5.2	103
24	Spliceosome-targeted therapies trigger an antiviral immune response in triple-negative breast cancer. <i>Cell</i> , 2021, 184, 384-403.e21.	28.9	94
25	PI3K/AKT Signaling Regulates H3K4 Methylation in Breast Cancer. <i>Cell Reports</i> , 2016, 15, 2692-2704.	6.4	92
26	Chromatin landscapes reveal developmentally encoded transcriptional states that define human glioblastoma. <i>Journal of Experimental Medicine</i> , 2019, 216, 1071-1090.	8.5	89
27	Discovery of a selective inhibitor of doublecortin like kinase 1. <i>Nature Chemical Biology</i> , 2020, 16, 635-643.	8.0	84
28	Stabilization of the Max Homodimer with a Small Molecule Attenuates Myc-Driven Transcription. <i>Cell Chemical Biology</i> , 2019, 26, 711-723.e14.	5.2	82
29	HDAC Inhibition Reverses Preexisting Diastolic Dysfunction and Blocks Covert Extracellular Matrix Remodeling. <i>Circulation</i> , 2021, 143, 1874-1890.	1.6	71
30	Signal-Dependent Recruitment of BRD4 to Cardiomyocyte Super-Enhancers Is Suppressed by a MicroRNA. <i>Cell Reports</i> , 2016, 16, 1366-1378.	6.4	70
31	A C19MC-LIN28A-MYCN Oncogenic Circuit Driven by Hijacked Super-enhancers Is a Distinct Therapeutic Vulnerability in ETMRs: A Lethal Brain Tumor. <i>Cancer Cell</i> , 2019, 36, 51-67.e7.	16.8	69
32	BET bromodomain proteins regulate enhancer function during adipogenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 2144-2149.	7.1	65
33	Enhancer-Mediated Oncogenic Function of the Menin Tumor Suppressor in Breast Cancer. <i>Cell Reports</i> , 2017, 18, 2359-2372.	6.4	59
34	NRL and CRX Define Photoreceptor Identity and Reveal Subgroup-Specific Dependencies in Medulloblastoma. <i>Cancer Cell</i> , 2018, 33, 435-449.e6.	16.8	52
35	Trisomy of a Down Syndrome Critical Region Globally Amplifies Transcription via HMGN1 Overexpression. <i>Cell Reports</i> , 2018, 25, 1898-1911.e5.	6.4	52
36	PAX8 activates metabolic genes via enhancer elements in Renal Cell Carcinoma. <i>Nature Communications</i> , 2019, 10, 3739.	12.8	49

#	ARTICLE	IF	CITATIONS
37	Combinatorial inhibition of PTPN12-regulated receptors leads to a broadly effective therapeutic strategy in triple-negative breast cancer. <i>Nature Medicine</i> , 2018, 24, 505-511.	30.7	47
38	ZFTAâ€“RELA Dictates Oncogenic Transcriptional Programs to Drive Aggressive Supratentorial Ependymoma. <i>Cancer Discovery</i> , 2021, 11, 2200-2215.	9.4	46
39	Modulating Androgen Receptor-Driven Transcription in Prostate Cancer with Selective CDK9 Inhibitors. <i>Cell Chemical Biology</i> , 2021, 28, 134-147.e14.	5.2	44
40	Orally bioavailable CDK9/2 inhibitor shows mechanism-based therapeutic potential in MYCN-driven neuroblastoma. <i>Journal of Clinical Investigation</i> , 2020, 130, 5875-5892.	8.2	40
41	Deregulation of the Ras-Erk Signaling Axis Modulates the Enhancer Landscape. <i>Cell Reports</i> , 2015, 12, 1300-1313.	6.4	37
42	Impact of the gut microbiota on enhancer accessibility in gut intraepithelial lymphocytes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 14805-14810.	7.1	37
43	Mechanistic basis and efficacy of targeting the β -cateninâ€“TCF7L2â€“JMJD6â€“c-Myc axis to overcome resistance to BET inhibitors. <i>Blood</i> , 2020, 135, 1255-1269.	1.4	27
44	IRF2 is a master regulator of human keratinocyte stem cell fate. <i>Nature Communications</i> , 2019, 10, 4676.	12.8	25
45	AMP-activated protein kinase links acetyl-CoA homeostasis to BRD4 recruitment in acute myeloid leukemia. <i>Blood</i> , 2019, 134, 2183-2194.	1.4	25
46	Non-overlapping Control of Transcriptome by Promoter- and Super-Enhancer-Associated Dependencies in Multiple Myeloma. <i>Cell Reports</i> , 2018, 25, 3693-3705.e6.	6.4	23
47	Targeted brachyury degradation disrupts a highly specific autoregulatory program controlling chordoma cell identity. <i>Cell Reports Medicine</i> , 2021, 2, 100188.	6.5	15
48	An oncogenic enhancer encodes selective selenium dependency in AML. <i>Cell Stem Cell</i> , 2022, 29, 386-399.e7.	11.1	15
49	A distinct core regulatory module enforces oncogene expression in KMT2A-rearranged leukemia. <i>Genes and Development</i> , 2022, 36, 368-389.	5.9	14
50	Targeting the ApoA1 locus for liver-directed gene therapy. <i>Molecular Therapy - Methods and Clinical Development</i> , 2021, 21, 656-669.	4.1	9
51	Transcriptional Plasticity Drives Leukemia Immune Escape. <i>Blood Cancer Discovery</i> , 2022, 3, 394-409.	5.0	8
52	Computational Drug Repositioning Identifies Potentially Active Therapies for Chordoma. <i>Neurosurgery</i> , 2021, 88, 428-436.	1.1	7
53	KLF15 cistromes reveal a hepatocyte pathway governing plasma corticosteroid transport and systemic inflammation. <i>Science Advances</i> , 2022, 8, eabj2917.	10.3	5
54	Defining the transcriptional control of pediatric AML highlights RARA as a superenhancer-regulated druggable dependency. <i>Blood Advances</i> , 2021, 5, 4864-4876.	5.2	4

#	ARTICLE	IF	CITATIONS
55	Springing an evolutionary trap on cancer. <i>Nature Genetics</i> , 2020, 52, 361-362.	21.4	1
56	Disruption Of Super Enhancer-Driven Cancer Dependencies In Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2013, 122, 3021-3021.	1.4	1
57	PDTM-22. A C19MC-LIN28A-MYCN ONCOGENIC CIRCUIT DRIVEN BY HIJACKED SUPER-ENHANCERS IS A DISTINCT THERAPEUTIC VULNERABILITY IN ETMRS " A LETHAL BRAIN TUMOR. <i>Neuro-Oncology</i> , 2019, 21, vi191-vi192.	1.2	0
58	EPEN-30. C11ORF95-RELA FUSION PROTEIN ENGAGES NOVEL GENOMIC LOCI TO DRIVE MURINE EPENDYMOMA GROWTH. <i>Neuro-Oncology</i> , 2020, 22, iii314-iii314.	1.2	0
59	RNA Regulator of Lipogenesis (RROL) Is a Novel Lncrna Mediating Protein-Protein Interaction at Gene Regulatory Loci Driving Lipogenic Programs in Multiple Myeloma. <i>Blood</i> , 2020, 136, 20-21.	1.4	0
60	Abstract 15707: Histone Deacetylase Inhibition Reverses Preexisting Diastolic Dysfunction and Blocks Covert Extracellular Matrix Remodeling. <i>Circulation</i> , 2020, 142, .	1.6	0
61	Targeting MM at the Nexus between Cell Cycle and Transcriptional Regulation Via CDK7 Inhibition. <i>Blood</i> , 2020, 136, 1-2.	1.4	0